Last year, I covered Bristol UK-based Astral Systems, wondering if its compact nuclear reactors could revolutionise cancer detection by scaling up the production of isotopes used in treatments, and perhaps go further.
Fast-forward a year, and the firm has hit a £23M first close of its Series A funding round, making it one of the largest hard-tech/deep-tech rounds raised outside London and potentially positioning Astral as the UK’s biggest nuclear fusion tech scale-up.
The round was led by Mercia Ventures, with Tees River, Daphni, Blast Club, Speedinvest and Playfair also participating. Total funding now stands at more than £28M.
But Astral is not selling the usual 20-year fusion-energy dream. Its near-term target remains nuclear medicine, producing the medical isotopes used in cancer diagnosis and treatment. More than 50M nuclear medicine procedures are performed each year globally, but supply chains remain fragile, centralised and heavily dependent on the old types of ageing nuclear reactors.
Astral claims its multi-state fusion reactors offer a more scalable way to produce those isotopes. The company expects its first isotopes to reach market in early 2027, working with partners including McMaster University in Canada and IPEN in Brazil on Actinium-225 and Lead-212, two radioisotopes critical to new cancer therapies.
The company already says it has three commercial fusion facilities operating, has generated more than £3M in revenue from research contracts, and says it is aiming for profitability in 2027.
The company is scaling from Bristol and developing a new facility at the former Berkeley Power Station in Gloucestershire, placing a bet on UK industrial heritage, nuclear talent and deep-tech growth outside the usual London-centric corridors.
Talmon Firestone, CEO and co-founder of Astral Systems, said in a statement: “We are rewriting how we approach fusion and, in doing so, redefining what it means to be a fusion company. This is evident in our novel technology and its near-term applications in modern medicine, as well as facilitating the search for hybrid energy. With this new funding we can accelerate our ambition of building a profitable, impactful fusion business.”
However, Astral still faces a competitive field. In medical isotopes, the landscape includes fusion-based isotope player SHINE Technologies, US radiopharmaceutical supplier NorthStar Medical Radioisotopes, Actinium-225 producer Niowave, Bill Gates-backed TerraPower Isotopes, BWXT Medical, cyclotron-based Ac-225 producer Ionetix, Germany’s ITM Isotope Technologies and Utah-based isotope platform Nusano.
